Avalyn Pharma Overview
- Year Founded
-
2011
- Status
-
Public
- Employees
-
51
- Stock Symbol
-
AVLN
- Share Price
-
$30.52
- (As of Thursday Closing)
Avalyn Pharma General Information
Description
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
Contact Information
Website
www.avalynpharma.comCorporate Office
- 105 West First Street
- Boston, MA 02127
- United States
Corporate Office
- 105 West First Street
- Boston, MA 02127
- United States
Avalyn Pharma Timeline
Avalyn Pharma Stock Performance
As of 12-Nov-2026, Avalyn Pharma’s stock price is $30.52. Its current market cap is $1.36B with 44.5M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $30.52 | $31.62 | $22.24 - $40.17 | $1.36B | 44.5M | 331K | -$2.47 |
Avalyn Pharma Financials Summary
As of 30-Jun-2026, Avalyn Pharma has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 |
|---|---|---|---|
| EV | 1,724,946 | ||
| Revenue | 0 | 0 | 0 |
| EBITDA | (109,871) | (91,339) | (57,154) |
| Net Income | (103,314) | (85,204) | (49,744) |
| Total Assets | 425,448 | 148,881 | 124,519 |
| Total Debt | 17,109 | 1,669 | 0 |
Avalyn Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Avalyn Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Avalyn Pharma Comparisons
Industry
Financing
Details
Avalyn Pharma Competitors (58)
One of Avalyn Pharma’s 58 competitors is Verona Pharma, a Corporate Backed or Acquired company based in London, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Verona Pharma | Corporate Backed or Acquired | London, United Kingdom | ||||
| Kyntra Bio | Formerly VC-backed | San Francisco, CA | ||||
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Minerva Neurosciences | Formerly VC-backed | Burlington, MA | ||||
| Idorsia Pharmaceuticals | Corporation | Allschwil, Switzerland |
Avalyn Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
News about Avalyn Pharma
Dive into recent articles by PitchBook offering invaluable insights and context.
Avalyn Pharma Patents
Avalyn Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026193088-A1 | Inhaled nintedanib (ap02) for idiopathic pulmonary fibrosis | Pending | 10-Mar-2025 | ||
| AU-2023280860-A1 | Nintedanib and nintedanib combination dry powder compositions and uses | Pending | 28-May-2022 | ||
| EP-4531809-A2 | Nintedanib and nintedanib combination dry powder compositions and uses | Pending | 28-May-2022 | ||
| EP-4531809-A4 | Nintedanib and nintedanib combination dry powder compositions and uses | Pending | 28-May-2022 | ||
| US-20250177294-A1 | Nintedanib and nintedanib combination dry powder compositions and uses | Pending | 28-May-2022 | A61K9/0075 |
Avalyn Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Avalyn Pharma ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Avalyn Pharma FAQs
-
When was Avalyn Pharma founded?
Avalyn Pharma was founded in 2011.
-
Where is Avalyn Pharma headquartered?
Avalyn Pharma is headquartered in Boston, MA.
-
What is the size of Avalyn Pharma?
Avalyn Pharma has 51 total employees.
-
What industry is Avalyn Pharma in?
Avalyn Pharma’s primary industry is Drug Discovery.
-
Is Avalyn Pharma a private or public company?
Avalyn Pharma is a Public company.
-
What is Avalyn Pharma’s stock symbol?
The ticker symbol for Avalyn Pharma is AVLN.
-
What is the current stock price of Avalyn Pharma?
As of 12-Nov-2026 the stock price of Avalyn Pharma is $30.52.
-
What is the current market cap of Avalyn Pharma?
The current market capitalization of Avalyn Pharma is $1.36B.
-
Who are Avalyn Pharma’s competitors?
Verona Pharma, Kyntra Bio, Sarepta Therapeutics, Minerva Neurosciences, and Idorsia Pharmaceuticals are some of the 58 competitors of Avalyn Pharma.
-
What is Avalyn Pharma’s annual earnings per share (EPS)?
Avalyn Pharma’s EPS for 12 months was -$2.47.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
